Table 1.
Clinical characteristics of patients with steroid-refractory chronic graft-versus-host disease.
| N (%) | |
|---|---|
| Age (median, range) | 35 (13-63) |
| Sex | |
| Male | 42 (60.0%) |
| Female | 28 (40.0%) |
| Diagnosis | |
| Acute myeloblastic leukemia | 24 (34.3%) |
| Acute lymphoblastic leukemia | 24 (34.3%) |
| Chronic myeloblastic leukemia | 5 (7.1%) |
| Chronic lymphoblastic leukemia | 1 (1.4%) |
| Myelodysplastic syndrome | 9 (12.9%) |
| Aplastic anemia | 4 (5.7%) |
| Non-Hodgkin lymphoma | 3 (4.3%) |
| Status at HSCT | |
| CR | 41 (58.6%) |
| PR | 2 (2.9%) |
| SD | 12 (17.1%) |
| Others | 15 (21.4%) |
| Type of transplant | |
| Matched donor | 29 (41.4%) |
| Haploidentical donor | 41 (58.6%) |
| Graft Source | |
| Peripheral blood stem cells | 32 (45.7%) |
| Bone marrow + Peripheral blood stem cells | 38 (54.3%) |
| Transplanted cell count (median, range) | |
| MNC (10^8/kg) | 11.4 (3.43-29.96) |
| CD34 (10^6/kg) | 3.80 (2.00-21.22) |
| GVHD prophylaxis | |
| CsA + MTX | 29 (41.4%) |
| CsA + MTX + MMF | 41 (58.6%) |
| Days of reconstitution after HSCT (median, range) | |
| NE > 1.0*10^9/L | 12 (10-23) |
| PLT > 20*10^9/L | 13 (8-80) |
| Complications | |
| Bacterial Infections | 49 (70.0%) |
| Hemorrhagic cystitis | 11 (15.7%) |
| CMV infection | 10 (14.3%) |
| EBV infection | 5 (7.1%) |
| aGVHD | |
| None | 28 (40.0%) |
| Grade 1-2 | 22 (31.4%) |
| Grade 3-4 | 20 (28.6%) |
HSCT, hematopoietic stem cell transplantation; CR, complete remission; PR, partial remission; SD, steady disease; MNC, mononuclear cell; CsA, cyclosporin A; MTX, methotrexate; MMF, mycophenolate mofetil; ATG, anti-thymocyte globulin; NE, neutrophil; PLT, platelet; CMV, cytomegalovirus; EBV, Epstein-Barr virus; aGVHD, acute graft-versus-host disease.